<DOC>
	<DOCNO>NCT00354484</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability VIT45 compare current standard care postpartum patient .</brief_summary>
	<brief_title>Safety Efficacy Hematinic Agent Treatment Postpartum Patients</brief_title>
	<detailed_description>This open label Phase III randomize active control study postpartum patient anemia . Patients randomize either active control investigational agent follow 6 week .</detailed_description>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Female Subjects able give consent Post partum patient Baseline Hgb &lt; /= 10 g/dL Agree practice birth control Participation previous clinical trial investigational agent Known hypersensitivity reaction active control Significant vaginal bleeding History anemia iron deficiency anemia Anticipated need surgery study Active severe infection malignancy Known positive Hepatitis B antigen Hepatitis C viral antibody Known HIV antibodies Received investigational drug within 30 day screen Alcohol abuse within past 6 month Hemochromatosis iron storage disorder Significant cardiovascular disease Any laboratory abnormality , medical condition severe psychiatric disorder opinion investigator woud put subject 's disease management risk may result subject able comply study requirement</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>postpartum</keyword>
</DOC>